Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
- PMID: 35691605
- DOI: 10.1016/j.ijantimicag.2022.106616
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
Abstract
Pharmacokinetic/pharmacodynamic (PKPD) models have emerged as valuable tools for the characterization and translation of antibiotic effects, and consequently for drug development and therapy. In contrast to traditional PKPD concepts for antibiotics such as minimum inhibitory concentration and PKPD indices, PKPD models enable description of the continuous, often species- or population-dependent time course of antimicrobial effects, commonly considering mechanistic pathogen- and drug-related knowledge. This review presents a comprehensive overview of previously published PKPD models describing repeated measurements of antibiotic effects. A literature review was conducted to identify PKPD models based on: (i) antibiotic compounds; (ii) Gram-positive or Gram-negative pathogens; and (iii) in-vitro or in-vivo longitudinal colony-forming unit data. In total, 132 publications were identified that were released between 1963 and 2021, including models based on exposure to single antibiotics (n=92) and drug combinations (n=40), as well as different experimental settings (e.g. static/traditional dynamic/hollow-fibre/animal time-kill models, n=90/27/32/11). An interactive, fully searchable table summarizes the details of each model, namely variants and mechanistic elements of PKPD submodels capturing observed bacterial growth, regrowth, drug effects and interactions. Furthermore, the review highlights the main purposes of PKPD model development, including the translation of preclinical PKPD to clinical settings, and the assessment of varied dosing regimens and patient characteristics for their impact on clinical antibiotic effects. In summary, this comprehensive overview of PKPD models will assist in identifying PKPD modelling strategies to describe growth, killing, regrowth and interaction patterns for pathogen-antibiotic combinations over time, and ultimately facilitate model-informed antibiotic translation, dosing and drug development.
Keywords: Antibiotics; Colony-forming units; Infection model; PKPD model; Pharmacokinetics/pharmacodynamics; Pharmacometrics.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interests None declared.
Similar articles
-
Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.Clin Microbiol Infect. 2018 Jul;24(7):697-706. doi: 10.1016/j.cmi.2017.11.023. Epub 2017 Dec 8. Clin Microbiol Infect. 2018. PMID: 29229429 Review.
-
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.Pharmacol Rev. 2013 Jun 26;65(3):1053-90. doi: 10.1124/pr.111.005769. Print 2013 Jul. Pharmacol Rev. 2013. PMID: 23803529 Review.
-
Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data.J Antimicrob Chemother. 2017 Nov 1;72(11):3108-3116. doi: 10.1093/jac/dkx269. J Antimicrob Chemother. 2017. PMID: 28961946
-
A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.J Antimicrob Chemother. 2020 Feb 1;75(2):400-408. doi: 10.1093/jac/dkz440. J Antimicrob Chemother. 2020. PMID: 31670804
-
Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Antimicrob Agents Chemother. 2011 Apr;55(4):1571-9. doi: 10.1128/AAC.01286-10. Epub 2011 Jan 31. Antimicrob Agents Chemother. 2011. PMID: 21282424 Free PMC article.
Cited by
-
Adaptation of an in vitro one-compartment pharmacodynamic chemostat for testing efficacy of ceftazidime against Burkholderia pseudomallei outside a BSL3 facility.MethodsX. 2025 Jan 10;14:103167. doi: 10.1016/j.mex.2025.103167. eCollection 2025 Jun. MethodsX. 2025. PMID: 39897649 Free PMC article.
-
Enhancing antibiotic therapy through comprehensive pharmacokinetic/pharmacodynamic principles.Front Cell Infect Microbiol. 2025 Feb 25;15:1521091. doi: 10.3389/fcimb.2025.1521091. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40070375 Free PMC article. Review.
-
Influence of β-lactam pharmacodynamics on the systems microbiology of gram-positive and gram-negative polymicrobial communities.Front Pharmacol. 2024 Jun 4;15:1339858. doi: 10.3389/fphar.2024.1339858. eCollection 2024. Front Pharmacol. 2024. PMID: 38895629 Free PMC article.
-
Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model.Sci Rep. 2024 May 22;14(1):11706. doi: 10.1038/s41598-024-61518-0. Sci Rep. 2024. PMID: 38778123 Free PMC article.
-
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. Antimicrob Agents Chemother. 2023. PMID: 37695298 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical